Light-Activated Nanoparticles May Treat Head and Neck Cancer

Penn State

UNIVERSITY PARK, Pa. — For patients with head and neck cancer, treatment can come at a high cost to their quality of life, affecting their ability to speak, swallow and even breathe due to invasive procedures. Now, Penn State researchers have developed a light-activated nanoparticle system with the long-term goal of shrinking tumors while limiting exposure to healthy tissue and improving patients' quality of life after cancer treatment. Penn State has licensed the technology to Illuminate Therapeutics, which is advancing its preclinical development.

In a study published in the Journal of Biomedical Materials Research , the researchers used nanoparticles made from layers of gold and silver to deliver a laboratory-made version of a small regulatory RNA molecule called microRNA-20a-5p. MicroRNAs help control which proteins cells produce, influencing processes such as cell growth and death. The nanoparticles were designed to release the microRNA only when exposed to near-infrared light, allowing the researchers to control where and when it was released in the body. In mice bearing tumors grown from human hypopharyngeal — or head and neck — cancer cells, a single dose followed by light activation reduced the volume of illuminated tumors by about 95% within 48 hours.

"Cancers in the head and neck affect our ability to speak, affect our ability to breathe, affect our ability to swallow, taste and communicate with society," said Neerav Goyal , a leader of the research team and professor in the Departments of Otolaryngology, of Neurosurgery, of Surgery and Public Health Sciences at Penn State College of Medicine.

For Goyal, who is also a head and neck surgical oncologist for Penn State Health, the potential benefit goes beyond reducing tumor size. By shrinking tumors before surgery, the technology could help physicians preserve tissues and organs that would otherwise be removed during cancer treatment, he said.

"You might be able to lessen the portion of the tongue, jaw, or other portions of the face to cure a cancer, and that would make their reconstruction easier, and likely lend to quality-of-life improvement with less side effects from treatment," Goyal said.

The technology grew out of a challenge that has long limited the use of available therapies to treat certain cancers: delivering enough treatment to the intended location without harming healthy parts of the body.

"We really set out to solve a very specific problem," said Daniel Hayes, a professor of biomedical engineering and the Dorothy Foehr Huck and J. Lloyd Huck Chair in Nanotherapeutics and Regenerative Medicine at Penn State and the corresponding author of the study.

Hayes explained that delivering genetic materials for cancer therapies, such as microRNA, throughout the body can lead to their accumulation in organs such as the liver, potentially causing harmful side effects.

"Our approach gives you precise control over the delivery of these therapeutics, which would otherwise be difficult to use safely when delivered systemically," said Hayes, who is also affiliated with Penn State's Huck Institutes of the Life Sciences and the Materials Research Institute.

To release the treatment, the researchers exposed the nanoparticles to a specific wavelength of near-infrared light. The particles converted the light into localized heat, triggering release of the microRNA at the illuminated site.

The researchers first tested the technology in human cancer cells grown in the laboratory. They examined whether the nanoparticles could enter cancer cells, release their microRNA cargo and influence the biological processes involved in cell survival and death. After observing promising results, the team tested the system in mice carrying tumors developed from human cancer cells.

In the mouse study, tumors exposed to light after treatment shrank substantially, while tumors that were not illuminated continued to grow.

"We had seen similar results in vitro but seeing that translate to the in vivo environment is really surprising to me," Hayes said, referring to the transition from experiments with cells grown in the laboratory to studies in living animals.

Despite promising preliminary results, Hayes emphasized that the technology remains at an early stage of development.

"Animal models do not translate directly to humans, and so there will be more research and clinical trials before we can really demonstrate that this technology is safe for humans," he said.

The idea behind the technology dates back more than a decade, Hayes said. He began developing light-responsive delivery systems in 2013, initially exploring how to control the release of therapeutic molecules in different parts of the body.

However, the research did not originally focus on head and neck cancer. That direction emerged through conversations between researchers and clinicians at Penn State College of Medicine and Penn State Health, including Douglas Stairs, associate professor of pathology and laboratory medicine and of neuroscience and experimental therapeutics at Penn State College of Medicine and Goyal, who recognized how the technology might address a major challenge in treating cancers in the head and neck region. The project illustrates how collaboration between Penn State's University Park and Hershey campuses can connect technological innovations with unmet clinical needs, Goyal explained.

"There are opportunities and avenues that exist within our institution to allow collaboration across disciplines, which allow for synergies that may not otherwise exist," he said.

Bringing the technology closer to patients will require additional research, extensive safety testing and specialized resources. Penn State has licensed the technology to Illuminate Therapeutics, which is advancing preclinical development through its Light Activated Drug Delivery and Release (LADDR) platform.

"It wouldn't be practical for my lab to do large scale preclinical and hopefully eventually clinical work," Hayes explained. "It's best to put this into the hands of a partner who's looking to commercialize it."

Beyond head and neck cancer, the researchers envision the nanoparticles as a broader delivery platform that could potentially be adapted to carry different therapeutic molecules and address other diseases.

"For now, the findings represent an early step toward a treatment approach that could localize where cancer therapies act," Goyal said.

The research team also included co-authors Angelica M. Helton, Tyus J. Yeingst, Lindsay P. Stone, and Dylan P. Kearse, postdoctoral scholars in the Department of Biomedical Engineering at Penn State.

This work was supported by the U.S. National Science Foundation award number 2033673 . This content is the sole responsibility of the authors and does not necessarily reflect the views of the funders.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.